



FOR IMMEDIATE RELEASE

Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting

West Chester, PA, June 17, 2019 -- Molecular Targeting Technologies, Inc. (MTTI) is an oncology company creating innovative products to see and treat cancer. MTTI's prime platforms are EBTATE (^{177}Lu -DOTA-EB-TATE) to treat Neuroendocrine Neoplasms (NENs) and a precision cell death targeting technology TDURA/TCP.

MTTI announced today that three abstracts highlighting these platforms were selected for oral and poster presentations at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting, June 22 – June 25, 2019 in Anaheim, California. MTTI will showcase its technology in booth #934, June 22-25, 2019 at SNMMI.

Details on the presentations :

Labeling Strategies of ^{18}F -duramycin for imaging cell apoptosis

Date & Time: Sunday, June 23, 2019 from 1:30 - 2:00 pm, Pacific Time

Oral Presentation-Session Title: Basic Science

Abstract No.: 1750

Comparative evaluation of TCP-1 molecular probes in colorectal and pancreatic cancer model

Date & Time: Sunday, June 23, 2019 from 6:30 - 8:00 pm, Pacific Time

Poster Session Title: Preclinical Probes for Oncology Posters

Abstract No.: 1046

Safety and Response of an Evans Blue-modified ^{177}Lu -labeled Octreotate in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study

Date & Time: Tuesday, June 25, 2019 from 3:00 to 4:30 pm, Pacific Time

Oral Presentation- Session 77 Title: Translational Image Guided

Abstract No.: 659

MTTI will showcase its technology in booth #934, June 22-25, 2019 at SNMMI.

EBTATE (^{177}Lu -DOTA-EB-TATE) Innovative science overcomes rapid clearance of the market leader in neuroendocrine neoplasm treatment. Incorporating Evans Blue (EB), an albumin binding agent, endows EBTATE with a substantially longer half-life, enabling much smaller, less frequent dosing of the radiotherapy to deliver the same therapeutic benefit.



TDURA (^{99m}Tc -duramycin) and **FGA** (^{18}F - glucaric acid) see apoptosis and necrosis respectively. Both visualize response to treatment of cancers shortly after onset of the therapy, reducing patient stress, cutting costs and improving outcomes. Both have demonstrated utility in imaging cardiac, inflammatory and pulmonary diseases.

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of disease.

More information: www.mtarget.com

Contact: Chris Pak, Email: cpak@mtarget.com ; Tel: (610) 738-7938